Journal
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Volume 14, Issue -, Pages S8-S11Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15412555.2017.1286166
Keywords
Alpha-1-antitrypsin deficiency; augmentation therapy; case finding; lung density
Categories
Funding
- AstraZeneca
- Boehringer-Ingelheim
- Chiesi
- CSL-Behring
- Grifols
- GSK
- Mundipharma
- Novartis
- Grifols SA (Barcelona, Spain)
Ask authors/readers for more resources
Alpha-1-antitrypsin deficiency (AATD) is one of the most frequent genetic causes of liver and lung diseases. Despite its known association with chronic obstructive pulmonary disease (COPD), AATD is largely unrecognised and underdiagnosed. Cases of AATD exist within every COPD or spirometry population but must be actively investigated. AATD is a laboratory diagnosis that must be confirmed by a blood test. A number of clinical clues' can raise suspicion of AATD, potentially facilitating earlier diagnosis and initiation of appropriate treatment. Alpha-1-antitrypsin augmentation therapy has a clear role in patients with severe AATD and a FEV1 <= 65% predicted. Emerging evidence suggests that attenuating the decline in lung density may prolong the time to respiratory failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available